

Davide Bedognetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5199566/publications.pdf>

Version: 2024-02-01

119
papers

10,458
citations

61984

43
h-index

39675

94
g-index

131
all docs

131
docs citations

131
times ranked

17725
citing authors

#	ARTICLE	IF	CITATIONS
1	miRNAs as novel immunoregulators in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2022, 124, 3-14.	5.0	11
2	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107.	9.4	124
3	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
4	Graphene oxide activates B cells with upregulation of granzyme B expression: evidence at the single-cell level for its immune-modulatory properties and anticancer activity. <i>Nanoscale</i> , 2022, 14, 333-349.	5.6	9
5	Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study. <i>Lancet Oncology</i> , The, 2022, 23, 341-352.	10.7	14
6	The immune landscape of solid pediatric tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	13
7	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. <i>British Journal of Cancer</i> , 2021, 124, 760-769.	6.4	13
8	BloodGen3Module: blood transcriptional module repertoire analysis and visualization using R. <i>Bioinformatics</i> , 2021, 37, 2382-2389.	4.1	18
9	Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry. <i>Npj Breast Cancer</i> , 2021, 7, 10.	5.2	11
10	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 74.	8.6	19
11	Insights Into the Role of CircRNAs: Biogenesis, Characterization, Functional, and Clinical Impact in Human Malignancies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 617281.	3.7	53
12	Germline genetic contribution to the immune landscape of cancer. <i>Immunity</i> , 2021, 54, 367-386.e8.	14.3	95
13	Network-based identification of key master regulators associated with an immune-silent cancer phenotype. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	11
14	2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2. <i>Nano Today</i> , 2021, 38, 101136.	11.9	63
15	Integrated transcriptionalâ€phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e434.	4.0	3
16	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. <i>Nature Communications</i> , 2021, 12, 4385.	12.8	29
17	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	14
18	Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus. <i>American Journal of Pathology</i> , 2021, 191, 1774-1786.	3.8	7

#	ARTICLE	IF	CITATIONS
19	Prospective validation study of prognostic biomarkers to predict adverse outcomes in patients with COVID-19: a study protocol. <i>BMJ Open</i> , 2021, 11, e044497.	1.9	14
20	Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 734959.	2.8	8
21	Impact of the surface functionalization on nanodiamond biocompatibility: a comprehensive view on human blood immune cells. <i>Carbon</i> , 2020, 160, 390-404.	10.3	27
22	Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data. <i>Immunology</i> , 2020, 161, 291-302.	4.4	32
23	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. <i>Nature Cancer</i> , 2020, 1, 1204-1217.	13.2	58
24	A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of Psoriasis. <i>Frontiers in Immunology</i> , 2020, 11, 587946.	4.8	19
25	Sterol synthesis pathway inhibition as a target for cancer treatment. <i>Cancer Letters</i> , 2020, 493, 19-30.	7.2	15
26	Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome. <i>Molecular Immunology</i> , 2020, 128, 205-218.	2.2	15
27	STXBP6, reciprocally regulated with autophagy, reduces triple negative breast cancer aggressiveness. <i>Clinical and Translational Medicine</i> , 2020, 10, e147.	4.0	3
28	A Multi-layer Molecular Fresco of the Immune Diversity across Hematologic Malignancies. <i>Cancer Cell</i> , 2020, 38, 313-316.	16.8	4
29	Definition of erythroid cell-positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection. <i>Clinical and Translational Medicine</i> , 2020, 10, e244.	4.0	22
30	A map of tumor-host interactions in glioma at single-cell resolution. <i>GigaScience</i> , 2020, 9, .	6.4	32
31	Graphene, other carbon nanomaterials and the immune system: toward nanoimmunity-by-design. <i>JPhys Materials</i> , 2020, 3, 034009.	4.2	29
32	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
33	Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. <i>Journal of Translational Medicine</i> , 2020, 18, 192.	4.4	7
34	Single-Cell Analysis: Toward High-Dimensional Single-Cell Analysis of Graphene Oxide Biological Impact: Tracking on Immune Cells by Single-Cell Mass Cytometry (<i>Small</i> 21/2020). <i>Small</i> , 2020, 16, 2070117.	10.0	3
35	Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. <i>ACS Nano</i> , 2020, 14, 6383-6406.	14.6	455
36	HLA-G: A New Immune Checkpoint in Cancer?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4528.	4.1	52

#	ARTICLE	IF	CITATIONS
37	Toward High-Dimensional Single-Cell Analysis of Graphene Oxide Biological Impact: Tracking on Immune Cells by Single-Cell Mass Cytometry. <i>Small</i> , 2020, 16, 2000123.	10.0	10
38	Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics. <i>Theranostics</i> , 2020, 10, 5435-5488.	10.0	80
39	Functional Genome Profiling to Understand Cancer Immune Responsiveness. <i>Methods in Molecular Biology</i> , 2020, 2055, 231-244.	0.9	0
40	The Biology of Immune-Active Cancers and Their Regulatory Mechanisms. <i>Cancer Treatment and Research</i> , 2020, 180, 149-172.	0.5	5
41	Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. <i>Frontiers in Immunology</i> , 2019, 10, 2410.	4.8	33
42	Photodynamic Therapy Based on Graphene and MXene in Cancer Theranostics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 295.	4.1	100
43	Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 335-343.	2.5	19
44	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. <i>Scientific Reports</i> , 2019, 9, 8572.	3.3	36
45	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
46	Monoallelic expression in melanoma. <i>Journal of Translational Medicine</i> , 2019, 17, 112.	4.4	2
47	Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1328.	2.8	13
48	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	14.3	3,706
49	Evolution of Metastases in Space and Time under Immune Selection. <i>Cell</i> , 2018, 175, 751-765.e16.	28.9	322
50	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	6.4	54
51	How can nanotechnology help the fight against breast cancer?. <i>Nanoscale</i> , 2018, 10, 11719-11731.	5.6	42
52	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
53	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. <i>Frontiers in Immunology</i> , 2018, 9, 947.	4.8	261
54	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. <i>Oncotarget</i> , 2018, 7, e1490854.	4.6	200

#	ARTICLE	IF	CITATIONS
55	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	4.6	146
56	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. <i>Oncolmmunology</i> , 2017, 6, e1323618.	4.6	42
57	Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. <i>Nature Communications</i> , 2017, 8, 1109.	12.8	111
58	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2229.	4.1	105
59	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 429-445.	2.6	45
60	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
61	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
62	Molecular and Genomic Impact of Large and Small Lateral Dimension Graphene Oxide Sheets on Human Immune Cells from Healthy Donors. <i>Advanced Healthcare Materials</i> , 2016, 5, 276-287.	7.6	90
63	Interferon- β and Tumor Necrosis Factor- α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. <i>Scientific Reports</i> , 2016, 6, 26345.	3.3	69
64	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. <i>Oncolmmunology</i> , 2016, 5, e1240857.	4.6	56
65	Disentangling the relationship between tumor genetic programs and immune responsiveness. <i>Current Opinion in Immunology</i> , 2016, 39, 150-158.	5.5	57
66	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	3.0	8
67	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. <i>Cancer Immunology Research</i> , 2016, 4, 600-610.	3.4	86
68	Conservation of immune gene signatures in solid tumors and prognostic implications. <i>BMC Cancer</i> , 2016, 16, 911.	2.6	70
69	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	1.4	45
70	Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations. <i>Journal of Translational Medicine</i> , 2016, 14, 22.	4.4	6
71	Defining genetic modulators of intratumoral immune response in breast cancer through a system biology approach. , 2016, , .		0
72	Toward the identification of genetic determinants of breast cancer immune responsiveness. , 2015, 3, P1.		4

#	ARTICLE	IF	CITATIONS
73	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 99-127.	0.4	4
74	Prognostic and predictive immune gene signatures in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 433-444.	2.4	75
75	The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015, 9, 93-104.	4.6	28
76	The immune-related role of BRAF in melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, K19.	4.4	0
77	Inherent transcriptional signatures of NK cells are associated with response to IFN γ + sorivabirin therapy in patients with Hepatitis C Virus. <i>Journal of Translational Medicine</i> , 2015, 13, 77.	4.4	8
78	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28 α -Costimulated T Cells Prepared for Adoptive Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2840-2850.	7.0	52
79	Meta-analysis and metagenes. <i>Oncolmmunology</i> , 2014, 3, e28727.	4.6	12
80	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 663-686.	3.1	17
81	Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme. <i>British Journal of Cancer</i> , 2014, 110, 2955-2964.	6.4	16
82	The perception of nanotechnology and nanomedicine: a worldwide social media study. <i>Nanomedicine</i> , 2014, 9, 1475-1486.	3.3	34
83	Impact of carbon nanotubes and graphene on immune cells. <i>Journal of Translational Medicine</i> , 2014, 12, 138.	4.4	104
84	Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer. , 2014, 2, .		2
85	Melanoma NOS1 expression promotes dysfunctional IFN signaling. <i>Journal of Clinical Investigation</i> , 2014, 124, 2147-2159.	8.2	40
86	The Immune-related Role Of Braf In Melanoma. , 2014, , .		0
87	Effects Of Rituximab On The Response To Influenza Vaccine In Complete Remission Lymphoma Patients. , 2014, , .		0
88	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. <i>Immunity</i> , 2013, 39, 11-26.	14.3	700
89	Common pathways to tumor rejection. <i>Annals of the New York Academy of Sciences</i> , 2013, 1284, 75-79.	3.8	17
90	Functionalized carbon nanotubes as immunomodulator systems. <i>Biomaterials</i> , 2013, 34, 4395-4403.	11.4	109

#	ARTICLE	IF	CITATIONS
91	BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. <i>Nature</i> , 2013, 498, 506-510.	27.8	332
92	Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. <i>Journal of Clinical Oncology</i> , 2013, 31, 2369-2371.	1.6	56
93	Molecular Profiling of Immunotherapeutic Resistance. , 2013, , 373-394.		2
94	IRF-1 responsiveness to IFN- β predicts different cancer immune phenotypes. <i>British Journal of Cancer</i> , 2013, 109, 76-82.	6.4	58
95	CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. <i>British Journal of Cancer</i> , 2013, 109, 2412-2423.	6.4	136
96	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. <i>Journal of Translational Medicine</i> , 2013, 11, 145.	4.4	82
97	Functionalized multiwalled carbon nanotubes as ultrasound contrast agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16612-16617.	7.1	139
98	Seasonal and pandemic (A/H1N1 2009) MF-59 \hat{a} €“adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. <i>Blood</i> , 2012, 120, 1954-1957.	1.4	16
99	The stable traits of melanoma genetics: an alternate approach to target discovery. <i>BMC Genomics</i> , 2012, 13, 156.	2.8	29
100	IRF5 gene polymorphisms in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 170.	4.4	36
101	Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. <i>Medical Oncology</i> , 2012, 29, 3456-3461.	2.5	10
102	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. <i>Pituitary</i> , 2012, 15, 209-214.	2.9	7
103	Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8576-8576.	1.6	2
104	Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. <i>BMC Cancer</i> , 2011, 11, 451.	2.6	20
105	An immunologic portrait of cancer. <i>Journal of Translational Medicine</i> , 2011, 9, 146.	4.4	83
106	SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery. <i>Journal of Translational Medicine</i> , 2011, 9, 155.	4.4	25
107	Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. <i>Journal of Translational Medicine</i> , 2011, 9, 174.	4.4	85
108	Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. <i>BMC Medical Genomics</i> , 2011, 4, 38.	1.5	73

#	ARTICLE	IF	CITATIONS
109	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens. <i>Journal of Immunology</i> , 2011, 186, 6044-6055.	0.8	93
110	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1529-1539.	6.3	27
111	Signatures Associated with Acute Rejection: Allograft Rejection. , 2011, , 305-345.		0
112	Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era. <i>International Journal of Hematology</i> , 2010, 91, 342-344.	1.6	6
113	An Open, Randomised, Multicentre, Phase 3 Trial Comparing the Efficacy of Two Tamoxifen Schedules in Preventing Gynaecomastia Induced by Bicalutamide Monotherapy in Prostate Cancer Patients. <i>European Urology</i> , 2010, 57, 238-245.	1.9	35
114	Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. <i>Experimental Hematology</i> , 2010, 38, 979-988.	0.4	48
115	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. <i>Clinical Cancer Research</i> , 2010, 16, 5862-5872.	7.0	56
116	Gene-expression profiling in vaccine therapy and immunotherapy for cancer. <i>Expert Review of Vaccines</i> , 2010, 9, 555-565.	4.4	63
117	Gynaecomastia: The Anastrozole Paradox. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2010, 23, 205-6.	0.9	1
118	Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a Persistent Depletion of B Memory Cells.. <i>Blood</i> , 2009, 114, 936-936.	1.4	1
119	Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2733-2733.	1.4	28